Disc Medicine, Inc.
Clinical trials sponsored by Disc Medicine, Inc., explained in plain language.
A clinical-stage biotech developing treatments for hematologic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could let Sun-Sensitive patients enjoy the outdoors Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for IBD patients with anemia: experimental drug enters trial Results expected Oct 2026 (estimated) May already have reported ↗
- New drug aims to reduce Blood-Letting in rare blood cancer Results expected Feb 2027 (estimated) May already have reported ↗
- New drug aims to cut blood transfusions for bone marrow disease patients Results expected May 2027 (estimated) May already have reported ↗
- New sickle cell drug DISC-3405 enters early human safety trial Results expected Jun 2027 (estimated) May already have reported ↗
-
New hope for kidney patients: experimental anemia drug shows promise
Disease control CompletedThis study tested a new drug called DISC-0974 in 55 adults with chronic kidney disease (not on dialysis) who also have anemia. The goal was to check the drug's safety and how the body processes it. Participants received either the drug or a placebo by injection. The results will …
Phase 1 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug offers hope for patients who Can't tolerate sunlight
Disease control CompletedThis study tested a drug called bitopertin in 75 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight exposure. The goal was to see if the drug is safe and can lower levels of a harmful substance in the blood. Participants receiv…
Phase 2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC